Sepe, Sara https://orcid.org/0000-0002-9884-9189
Rey, Federica https://orcid.org/0000-0001-7944-3143
Mancheno-Ferris, Alexandra https://orcid.org/0000-0002-2689-8483
Bigi, Alessandra https://orcid.org/0000-0002-1067-6288
Fani, Giulia
Damiani, Devid
Cabrini, Matteo
Marinelli, Eugenia
Aguado, Julio
Contu, Liliana
di Lillo, Alessia
Boggio, Sara
Tavella, Sara
Rosso, Ilaria
Gustincich, Stefano
Chiti, Fabrizio https://orcid.org/0000-0002-1330-1289
d’Adda di Fagagna, Fabrizio https://orcid.org/0000-0002-9603-5966
Funding for this research was provided by:
EC | European Research Council (ERC advanced grant -TELORNAGING-835103)
EC | European Research Council (ERC POC TELOVACCINE - 101113229)
Fondazione Telethon (GMR23T2007)
Fondazione Telethon (GMR23T2007)
Ministero dell'Università e della Ricerca ((PRIN) 2020CXFL4T)
Ministero dell'Università e della Ricerca ((PRIN) 2022R7LH5T)
Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica (FG_24/2020)
Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica (FG_24_2020)
Fondazione AIRC per la ricerca sul cancro ETS (AIRC-IG 30471)
Fondazione AIRC per la ricerca sul cancro ETS (AIRC-IG 21762)
Fondazione AIRC per la ricerca sul cancro ETS (AIRC 5×1000 21091)
European Commission (Next generation EU,PE8 Project Age-It)
European Commission (Next generation EU,PE8 Project Age-It)
European Commission (Investment CN3 National Center for Gene Therapy and Drugs based on RNA Technology)
European Commission (NEXTGENERATIONEU)
POR FESR InterSLA (DSB.AD004.294)
Fondazione Regionale per la Ricerca Biomedica (EJPRD19-206 PROGERIA,GA 825575)
Article History
Received: 18 November 2024
Revised: 1 July 2025
Accepted: 4 July 2025
First Online: 21 September 2025
Disclosure and competing interest statement
: F.d’A.d.F. is an inventor on the patent applications RNA products and uses thereof (PCT/EP2013/ 059753) and therapeutic oligonucleotides (PCT/EP2016/068162). F.d’A.d.F. is a shareholder of TAG Therapeutics. The remaining authors declare no competing interests.